(Q74191791)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9468355%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

The new antipsychotics, and their potential for early intervention in schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9468355%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

J L Waddington

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9468355%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

P J Scully

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9468355%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

E O'Callaghan

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9468355%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 December 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9468355%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

published in

Schizophrenia Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9468355%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9468355%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

2-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9468355%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

207-222

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9468355%20AND%20SRC:MED&resulttype=core&format=json

Pharmacological actions of the atypical antipsychotic drug clozapine: a review

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Clozapine. A novel antipsychotic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Negative labelling of individuals with first episode schizophrenia: the effect of premorbid functioning.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Treatment-resistant schizophrenia: clinical experience with new antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Treatment of negative symptoms in schizophrenia with amisulpride

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Serotonin, schizophrenia and antipsychotic drug action

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Clozapine: efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Patient response and resource management: another view of clozapine treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

A randomised controlled trial of prophylactic neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug action

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Conventional antipsychotic medications for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Activity of “Seroquel” (ICI 204,636) in Animal Models for Atypical Properties of Antipsychotics: A Comparison with Clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

The effect of clozapine on Fos protein immunoreactivity in the rat forebrain is not mimicked by the addition of alpha 1-adrenergic or 5HT2 receptor blockade to haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Course of schizophrenia: neuropsychological evidence for a static encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Amelioration of negative symptoms in schizophrenia by glycine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

1 reference

7 January 2021

Serotonin-dopamine interaction and its relevance to schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Duration of psychosis and outcome in first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

[11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Risperidone: how good is the evidence for efficacy?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Early detection and intervention in schizophrenia: editor's introduction

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

EPPIC: an evolving system of early detection and optimal management

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Clozapine: is another view valid?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Clozapine's effect on negative symptoms in treatment-refractory schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Putting the 'A' in atypical: does α2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Adverse effects of antipsychotic agents. Do newer agents offer advantages?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Prospects for pharmacotherapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Discriminative stimulus control with olanzapine: generalization to the atypical antipsychotic clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Effects of olanzapine on regional C-Fos expression in rat forebrain.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Clinical implications of clozapine discontinuation: report of an NIMH workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

"Awakenings" effect with risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: Similarities to clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Course of treatment response in first-episode and chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Risperidone: efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Contrasting effects of chronic clozapine, Seroquel(TM) (ICI 204,636) and haloperidol administration of deltaFosB-like immunoreactivity in the rodent forebrain

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Schizophrenia: developmental neuroscience and pathobiology

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Developmental trajectory and disease progression in schizophrenia: the conundrum, and insights from a 12-year prospective study in the Monaghan 101.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

From neuropathology to neurodevelopment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Time required for initial improvement during clozapine treatment of refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Neuroleptics and the Natural Course of Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

Early intervention for schizophrenia: can the course of the illness be altered?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900115-1

7 January 2021

10.1016/S0920-9964(97)00115-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9468355%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference